Vascular endothelial growth factor affects dendritic cell activity in hypertensive disorders of pregnancy

Wang,Jing; Tao,Yu‑Mei; Cheng,Xiao‑Yan; Zhu,Tian‑Feng; Chen,Zhi‑Fang; Yao,Hui; Su,Liang‑Xiang

doi:10.3892/mmr.2015.3783

Vascular endothelial growth factor affects dendritic cell activity in hypertensive disorders of pregnancy

Authors:
- Jing Wang
- Yu‑Mei Tao
- Xiao‑Yan Cheng
- Tian‑Feng Zhu
- Zhi‑Fang Chen
- Hui Yao
- Liang‑Xiang Su
View Affiliations

Affiliations: Department of Laboratory Medicine, Nantong Women and Children Health Care Hospital, Nantong, Jiangsu 226018, P.R. China, Department of Pathology, Nantong Women and Children Health Care Hospital, Nantong, Jiangsu 226018, P.R. China, Department of Obstetrics, Nantong Women and Children Health Care Hospital, Nantong, Jiangsu 226018, P.R. China, Department of Nursing, Nantong Women and Children Health Care Hospital, Nantong, Jiangsu 226018, P.R. China
Published online on: May 14, 2015 https://doi.org/10.3892/mmr.2015.3783
Pages: 3781-3786

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) activity is involved in the growth and stability of the placenta, and its signaling has been implicated in the development of pregnancy‑induced hypertension (PIH). The present study sought to evaluate VEGF levels and dendritic cell (DC) profiles in patients with PIH, and to investigate the effects of VEGF expression on DC phenotypes. The present study assessed 162 patients, 112 of whom were diagnosed with PIH. Serum VEGF was measured by ELISA, while myeloid DC (mDC; (Lin1‑HLA‑DR+CD11c+) and plasmacytoid DC (pDC; Lin1‑HLA‑DR+CD123+) counts were determined using flow cytometry. In order to determine the effect of VEGF treatment on DC phenotypes, immature DCs (iDCs) were separated from monocytes by culturing in the presence of cytokines (GM‑CSF, IL‑4), and then pretreated with VEGF or lipopolysaccharide (LPS). The phenotype of dendritic cells (CD14, CD80, CD83, or CD86) was determined by flow cytometry. The levels of VEGF in the serum of patients with PIH were significantly lower than those in control subjects (P<0.05). The percentage of pDCs found in the serum of patients with preeclampsia was significantly lower than that in the other groups. The percentage of mDCs in the serum of patients with preeclampsia and eclampsia was significantly higher than that in the control and hypertensive disorder groups (P<0.05). The percentage of mDCs was significantly negatively correlated with the levels of VEGF in the preeclamptic and eclamptic patients (r=‑0.34 and r=‑0.42, respectively; P<0.05). Detected levels of CD80, CD83 and CD86 in DCs treated with VEGF were significant lower than those in DCs treated with LPS alone (P<0.05). In conclusion, abnormal expression of VEGF and an altered dendritic cell profile may be involved in the development of PIH.

View Figures

View References

1	Gaio DS, Schmidt MI, Duncan BB, et al: Hypertensive disorders in pregnancy: Frequency and associated factors in a cohort of Brazilian women. Hypertens Pregnancy. 20:269–281. 2001. View Article : Google Scholar
2	Lykke JA, Langhoff-Roos J, Sibai BM, et al: Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 53:944–951. 2009. View Article : Google Scholar : PubMed/NCBI
3	Nahar L, Nahar K, Hossain MI, Jahan S and Rahman MM: Placental changes in pregnancy induced hypertension. Mymensingh Med J. 22:684–693. 2013.PubMed/NCBI
4	Nahar L, Nahar K, Hossain MI, Yasmin H and Annur BM: Placental changes in pregnancy induced hypertension and its impacts on fetal outcome. Mymensingh Med J. 24:9–17. 2015.PubMed/NCBI
5	LaMarca B, Cornelius D and Wallace K: Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda). 28:225–233. 2013.
6	Cao X, Wang LL and Luo X: Expression of regulatory T and helper T cells in peripheral blood of patients with pregnancy-induced hypertension. Clin Exp Obstet Gynecol. 40:502–504. 2013.PubMed/NCBI
7	Kalkunte SS, Mselle TF, Norris WE, et al: Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol. 182:4085–4092. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tripathi R, Ralhan R, Saxena S, et al: Soluble VEGFR-1 in pathophysiology of pregnancies complicated by hypertensive disorders: The Indian scenario. J Human Hypertens. 27:107–114. 2012. View Article : Google Scholar
9	Geissmann F, Auffray C, Palframan R, et al: Blood monocytes: Distinct subsets, how they relate to dendritic cells and their possible roles in the regulation of T-cell responses. Immunol Cell Biol. 86:398–408. 2008. View Article : Google Scholar : PubMed/NCBI
10	van de Laar L, Buitenhuis M, Wensveen FM, et al: Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling. J Immunol. 184:6600–6611. 2010. View Article : Google Scholar : PubMed/NCBI
11	Laxmanan S, Robertson SW, Wang E, et al: Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Comm. 334:193–198. 2005. View Article : Google Scholar : PubMed/NCBI
12	Oyama T, Ran S, Ishida T, et al: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 160:1224–1232. 1998.PubMed/NCBI
13	Seetharam L, Gotoh N, Maru Y, et al: A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10:135–147. 1995.PubMed/NCBI
14	Schonkeren D, van der Hoorn ML, Khedoe P, et al: Differential distribution and phenotype of decidual macrophages in preeclamptic versus control pregnancies. Am J Pathol. 178:709–717. 2011. View Article : Google Scholar : PubMed/NCBI
15	Stober D, Schirmbeck R and Reimann J: IL-12/IL-18-dependent IFN-γ release by murine dendritic cells. J Immunol. 167:957–965. 2001. View Article : Google Scholar : PubMed/NCBI
16	Block MS, Nevala WK, Leontovich AA, et al: Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res. 17:1776–1783. 2011. View Article : Google Scholar : PubMed/NCBI
17	Chen Z, Varney ML, Backora MW, et al: Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65:9004–9011. 2005. View Article : Google Scholar : PubMed/NCBI
18	Vicari AP, Treilleux I and Lebecque S: Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol. 14:161–169. 2004. View Article : Google Scholar : PubMed/NCBI
19	Berger S, Dyugovskaya L, Polyakov A, et al: Short-term fibronectin treatment induces endothelial-like and angiogenic properties in monocyte-derived immature dendritic cells: involvement of intracellular VEGF and MAPK regulation. Eur J Cell Biol. 91:640–653. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mahnke K, Schmitt E, Bonifaz L, et al: Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol. 80:477–483. 2002. View Article : Google Scholar : PubMed/NCBI
21	Sugiyama M, Kakeji Y, Tsujitani S, et al: Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites. Mol Cancer Ther. 10:540–549. 2011. View Article : Google Scholar : PubMed/NCBI